

17. 研究結果の発表

研究結果の学会・論文発表に際しては、発表時点での JCOG 全体または研究グループで決定されたポリシーに従う。発表時点で明確な JCOG または研究グループのポリシーが定まっていない場合、以下の原則に従う。

主たる公表論文は最終解析終了後に英文誌に投稿する。

プロトコルで規定された最終解析または公表目的での中間解析がプロトコルに明記されている以外は、効果・安全性評価委員会の承認を得た場合を除いて発表は行わない。

ただし、研究代表者または研究事務局は、研究のエンドポイントの解析結果を含まない、研究の紹介目的の学会・論文(総説)発表は研究グループ代表者および JCOG データセンター長の了承を経て行うことができる。

原則として、研究結果の主たる公表論文の著者は筆頭を研究事務局とし、以下、研究代表者、データセンターの統計担当(公表のための解析を行った時点での担当者 1 名)、グループ代表者の順とする。それ以下は、論文の投稿規定による制限に従って、登録数の多い順に施設研究責任者または施設コーディネーターを施設毎に選び共著者とする。すべての共著者は投稿前に論文内容を review し、発表内容に合意した者のみとする。内容に関して議論にても合意が得られない場合、研究代表者はグループ代表者の了承の上で、その研究者を共著者に含めないことができる。

学会発表は複数回に及ぶ可能性があるため、研究事務局、研究代表者、登録の多い施設の研究責任者または施設コーディネーターの中から、持ち回りで発表を行うこととする。発表者は研究代表者がグループ代表者の了承を得て決定する。ただし、学会発表に際しては、発表準備および発表内容について研究事務局が責任を持ち、原則としてデータセンターとの連絡は研究事務局が行う。研究事務局以外の発表者が、研究事務局と JCOG データセンター長の了承なく、直接データセンターから集計・解析結果を受け取ることはできない。

18. 参考文献

1. FIGO Committee on Gynecologic Oncology, FIGO Annual Report on the Results of Treatment in Gynecological Cancer: Statements of results obtained in patients treated in 1993-95, inclusive overall survival up to 2000., 2000.
2. Rosen A, Klein M, Lahousen M, Graf AH, Rainer A, and Vavra N, Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma., *Br J Cancer*, 68: 605-9, 1993.
3. Dalrymple JC, Bannatyne P, Russell P, Solomon HJ, Tattersall MH, Atkinson K, Carter J, Duval P, Elliott P, Friedlander M, Murray J, and Coppleson M, Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases., *Cancer*, 64: 110-5, 1989.
4. White PF, Merino MJ, and Barwick KW, Serous surface papillary carcinoma of the ovary: a clinical, pathologic, ultrastructural, and immunohistochemical study of 11 cases., *Pathol Annu*, 20 Pt 1: 403-18, 1985.
5. Lele SB, Piver MS, Matharu J, and Tsukada Y, Peritoneal papillary carcinoma., *Gynecol Oncol*, 31: 315-20, 1988.
6. Peters WA,III, Andersen WA, and Hopkins MP, Results of chemotherapy in advanced carcinoma of the fallopian tube., *Cancer*, 63: 836-8, 1989.
7. がんの統計編集委員会, がんの統計'05, 2005.
8. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer., *JAMA*, 273: 491-7, 1995.
9. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, and Major F, Jr., Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials., *N Engl J Med*, 322: 1021-7, 1990.
10. Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV, Jeffrey JF, and Pater JL, Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging., *Gynecol Oncol*, 43: 195-7, 1991.
11. Trimbos JB, Schueler JA, van der Burg M, Hermans J, van Lent M, Heintz AP, and Fleuren GJ, Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer., *Cancer*, 67: 597-602, 1991.
12. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, and Pecorelli S, Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial., *J Natl Cancer Inst*, 95: 113-25, 2003.
13. Molina R, Ojeda B, Filella X, Borrás G, Jo J, Mas E, Lopez JJ, and Ballesta A, A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas., *Tumour Biol*, 13: 278-86, 1992.
14. DiSaia, P. J., Creasman, W. T., *Clinical Gynecologic Oncology Sixth Edition*, 2002.
15. Eltabbakh GH, Belinson JL, Kennedy AW, Gupta M, Webster K, and Blumenson LE, Serum CA-125 measurements > 65 U/mL. Clinical value., *J Reprod Med*, 42: 617-24, 1997.
16. Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Jr., and Knapp RC, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer., *N Engl J Med*, 309: 883-7, 1983.
17. Parente JT, and Greston WM, Carcinoembryonic antigen levels in the diagnosis of malignant lesions of the abdominopelvic region., *Surg Gynecol Obstet*, 153: 693-6, 1981.
18. Onda T, Yoshikawa H, Yokota H, Yasugi T, and Taketani Y, Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy., *Cancer*, 78: 803-8, 1996.

19. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Mancini N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, and Mangioni C, Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial., *J Natl Cancer Inst*, 97: 560-6, 2005.
20. Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, and Steren A, National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system., *Cancer*, 72: 3007-11, 1993.
21. Hogberg T, Carstensen J, and Simonsen E, Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer., *Gynecol Oncol*, 48: 38-49, 1993.
22. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, and Boyes DA, Ovarian carcinoma: a multivariate analysis of prognostic factors., *Obstet Gynecol*, 65: 264-270, 1985.
23. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz AP, van Lent M, Trimbos JB, Bouma J, Vermorken JB, and van Hauwelingen JC, Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma., *J Clin Oncol*, 5: 1157-1168, 1987.
24. Bertelsen K, Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study., *Gynecol Oncol*, 38: 203-9, 1990.
25. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, and Park RC, Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience., *J Clin Oncol*, 9: 1138-50, 1991.
26. Griffiths CT, Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma., *Natl Cancer Inst Monogr*, 42: 101-4, 1975.
27. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, and Kaye SB, Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma., *J Natl Cancer Inst*, 96: 1682-91, 2004.
28. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, and Pfisterer J, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer., *J Natl Cancer Inst*, 95: 1320-9, 2003.
29. Covens AL, A critique of surgical cytoreduction in advanced ovarian cancer., *Gynecol Oncol*, 78: 269-74, 2000.
30. Vogl SE, Pagano M, Kaplan BH, Greenwald E, Arseneau J, and Bennett B, Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens., *Cancer*, 51: 2024-30, 1983.
31. Delgado G, Oram DH, and Petrilli ES, Stage III epithelial ovarian cancer: the role of maximal surgical reduction., *Gynecol Oncol*, 18: 293-8, 1984.
32. Conte PF, Sertoli MR, Bruzzzone M, Rubagotti A, Rosso R, Bentivoglio G, Conio A, and Pescetto G, Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer., *Gynecol Oncol*, 20: 290-7, 1985.
33. Louie KG, Ozols RF, Myers CE, Ostchega Y, Jenkins J, Howser D, and Young RC, Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma., *J Clin Oncol*, 4: 1579-85, 1986.
34. Hainsworth JD, Grosh WW, Burnett LS, Jones HW, III, Wolff SN, and Greco FA, Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration., *Ann Intern Med*, 108: 165-70, 1988.

35. Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, and Ehrlich CE, Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma., *J Clin Oncol*, 7: 223-9, 1989.
36. Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, and Zanon V, Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment., *Gynecol Oncol*, 53: 27-32, 1994.
37. Go RS, and Adjei AA, Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin., *J Clin Oncol*, 17: 409-22, 1999.
38. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, and Arbuck SG, Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study., *J Clin Oncol*, 21: 2843-8, 2003.
39. du Bois A, Luck HJ, Bauknecht T, Mobus V, Bochtler H, Diergarten K, and Meerpohl HG, Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer., *Ann Oncol*, 8: 355-61, 1997.
40. Bookman MA, McGuire WP III, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, and Ozols RF, Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group., *J Clin Oncol*, 14: 1895-902, 1996.
41. Siddiqui N, Boddy AV, Thomas HD, Bailey NP, Robson L, Lind MJ, and Calvert AH, A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer., *Br J Cancer*, 75: 287-94, 1997.
42. Bolis G, Scarfone G, Villa A, Acerboni S, Siliprandi V, and Guarnerio P, A phase I trial with fixed-dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer., *Semin Oncol*, 24: No 1, Supple 2, 23-5, 1997.
43. Lhomme C, Kerbrat P, Lejeune C, Guastalla JP, Fumoleau P, Goupil A, Heron JF, Cassin MA, Pruvot I, Soares JA, and Chazard M, Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study., *Semin Oncol*, 23: No 5, Supple 12, 48-54, 1996.
44. Huizing MT, van Warmerdam LJ, Rosing H, Schaeffers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, and ten Bokkel Huinink WW, Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer., *J Clin Oncol*, 15: 1953-64, 1997.
45. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, and Baergen R, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study., *J Clin Oncol*, 21: 3194-200, 2003.
46. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, and van Houwelingen HC, Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer., *J Clin Oncol*, 18: 3084-92, 2000.
47. Kuzuya K, Ishikawa H, Nakanishi T, Kikkawa F, Nawa A, Fujimura H, Iwase A, Arii Y, Kawai M, Hattori S, Sakakibara K, Sasayama E, Furuhashi Y, Suzuki T, and Mizutani S, Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study., *Int J Clin Oncol*, 6: 271-8, 2001.
48. Bookman MA, Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182)., *Semin Oncol*, 29: No 1, Supple 1, 20-31, 2002.
49. Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, and Kainz C, Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity., *Anticancer Res*, 20: 4047-50, 2000.

50. ten Bokkel Huinink WW, van Warmerdam LJ, Helmerhorst TJ, Schaeffers MC, Beijnen JH, and Rodenhuis S, Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer., *Ann Oncol*, 8: 351-4, 1997.
51. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, and Graeff H, Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma., *Cancer*, 92: 2585-91, 2001.
52. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, and Wharton JT, Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer., *Gynecol Oncol*, 42: 146-50, 1991.
53. Onnis A, Marchetti M, Padovan P, and Castellan L, Neoadjuvant chemotherapy in advanced ovarian cancer., *Eur J Gynaecol Oncol*, 17: 393-6, 1996.
54. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, and Thiel RP, Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival., *Gynecol Oncol*, 72: 93-9, 1999.
55. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, and van Dam P, Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients., *Gynecol Oncol*, 71: 431-6, 1998.
56. Kayikcioglu F, Kose MF, Boran N, Caliskan E, and Tulunay G, Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma., *Int J Gynecol Cancer*, 11: 466-70, 2001.
57. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, and Pecorelli S, The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer., *N Engl J Med*, 332: 629-634, 1995.
58. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, and Small JM, Secondary surgical cytoreduction for advanced ovarian carcinoma., *N Engl J Med*, 351: 2489-97, 2004.
59. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, and Lewis JL, Jr., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin., *J Clin Oncol*, 9: 389-93, 1991.
60. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, and Trope C, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial., *Lancet*, 361: 2099-106, 2003.
61. Pfisterer J, Plante M, Vergote I, Du Bois A, Wagner U, Hirte H, Lacave AJ, Stahle A, Kimmig R and Eisenhauer E, Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG., *Proc Am Soc Clin Oncol*, (Abstract 5005), 2004.
62. 日本産科婦人科学会編, 卵巣腫瘍取り扱い規約第2部第1版, 1992.
63. Shepherd JH, Revised FIGO staging for gynaecological cancer., *Br J Obstet Gynaecol*, 96: 889-92, 1989.
64. 日本産科婦人科学会/日本病理学会編, 卵巣腫瘍取り扱い規約第1部第1版, 1990.
65. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, and Young LS, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer., *Clin Infect Dis*, 34: 730-51, 2002.
66. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, and Gwyther SG, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada., *J Natl Cancer Inst*, 92: 205-16, 2000.
67. O'Brien PC, and Fleming TR, A multiple testing procedure for clinical trials., *Biometrics*, 35: 549-56, 1979.

19. 付表 Appendix

- 説明文書・同意書
- Performance status scale(ECOG)
- 体表面積表
- 毒性規準(NCI-CTCAE ver.3.0 日本語訳 JCOG/JSCO 版)
- ケースレポートフォーム一式